Tailoring antiviral therapy in chronic hepatitis B patients with lamivudine resistance

Journal of Hepatology

Volumn 46, Issue 5, 2007, Pages 756-758

  Brunetto, Maurizia Rossana ^a  

^a UNIVERSITY HOSPITAL OF PISA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR DIPIVOXIL; ANTIVIRUS AGENT; EMTRICITABINE; ENTECAVIR; LAMIVUDINE; NUCLEOSIDE DERIVATIVE; TELBIVUDINE; TENOFOVIR DISOPROXIL;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; BIOAVAILABILITY; CHRONIC HEPATITIS; DISEASE COURSE; DRUG DOSE COMPARISON; DRUG RESPONSE; EDITORIAL; HEPATITIS B; HUMAN; MONOTHERAPY; NEPHROTOXICITY; PATIENT COMPLIANCE; PRIORITY JOURNAL; VIREMIA; VIRUS REPLICATION;

ADENINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, VIRAL; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; PHOSPHONIC ACIDS;

EID: 34147121932     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2007.02.016     Document Type: Editorial

References (37)

1. Lok A.S., and McMahon B.J. Chronic hepatitis B. Hepatology 45 (2007) 507-509
2. Zoulim F. Antiviral therapy of chronic hepatitis B. Antiviral Res 71 (2006) 206-215
3. Fung S.K., and Lok A.S. Management of hepatitis B patients with antiviral resistance. Antivir Ther 9 (2004) 1013-1398
4. Perrillo R. Antiviral therapy of chronic hepatitis B. Semin Liv Dis 25 (2005) 20-28
5. Bartholomeusz A., and Locarnini S. Antiviral drug resistance: clinical consequences and molecular aspects. Semin Liv Dis 26 (2006) 162-170
6. Peters M.G., Hann H.W., Martin P., Heathcote E.J., Buggisch P., Rubin R., et al. Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology 126 (2004) 91-101
7. Perrillo R., Hann H.W., Mutimer D., Willems B., Leung N., Lee W.M., et al. Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus. Gastroenterology 126 (2004) 81-91
8. Sherman M., Yurdaydin C., Sollano J., Silva M., Liaw Y.-F., and Cianciara J. Entecavir for treatment of lamivudine-refractory, HBeAg positive chronic hepatitis B. Gastroenterology 130 (2006) 2039-2049
9. Wong N.S., and Lok A.S. Tenfovir Disoproxil Fumarate: role in hepatitis B treatment. Hepatology 44 (2006) 309-312
10. Locarnini S., and Mason W.S. Cellular and virological mechanisms of HBV drug resistance. J Hepatol 44 (2006) 422-431
11. Tenney D.J., Levine S.M., Rose R.E., Walsh A.W., Weinheimer S.P., and Discotto L. Clinical emergence of entecavir-resistant hepatitits B virus requires additional substitutions in virus already resistant to Lamivudine. Antimicrob Agents Chemother 48 (2004) 3498-3507
12. Colonno R.J., Rose R., Baldick C.J., Levine S., Pokornowski K., Yu C.F., et al. Entecavir resistance is rare in nucleoside naïve patients with hepatitis B. Hepatology 44 (2006) 1656-1665
13. Zoulim F. Hepatitits B virus resistance to entecavir in nucleoside naïve patients: does it exist?. Hepatology 44 (2006) 1404-1407
14. Fung S.K., Chae H.B., Fontana R.J., Conjeevaram H., Marrero J., Oberhelman K., et al. Virologic response and resistance to adefovir in patients with chronic hepatitis B. J Hepatol 44 (2006) 283-290
15. VanBommel F., Zollner B., Sarrazin C., Spenler U., Huppe D., Moller B., et al. Tenofovir for patients with lamivudine-resistant hepatitis B virus (HBV) infection and high HBV-DNA level during adefovir therapy. Hepatology 44 (2006) 318-325
16. Lampertico P., Marzano A., Levrero M., Santatonio T., Andreone P., and Brunetto M.R. A multicenter Italian study of rescue adefovir dipivoxil therpy in lamivudine resistant patients: a 2 year analysis of 604 patients. Hepatology 42 (2006) 519A
17. Rapti I., Dimou E., Mitsoula P., and Hadziyannis S.J. Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitits B. Hepatology 45 (2007) 307-313
18. Suzuki F., Kumada H., and Nakamura H. Changes in viral loads of lamivudine-resistant mutants and evolution of HBV sequences during adefovir dipivoxil therapy. J Med Virol 78 (2006) 1025-1034
19. Villet S., Pichoud C., Villeneuve J.P., Trepo C., and Zoulim F. Selection of a multiple drug-resistant hepatitis B virus strain in a liver-transplanted patient. Gastroenterology 131 (2006) 1253-1261
20. Yim H.J., Hussain M., Lyu Y., Wong S.N., Fung S.K., and Lok A.S. Evolution of multi-drug resistant hepatitis B virus during sequential therapy. Hepatology 44 (2006) 703-712
21. Locarnini S., Qi X., arterbun S., Snow A., Brosgart C.L., and Currie G. Incidence and predictors of emergence of adefovir resistant HBV during 4 years of adefovir dipivoxil therapy for patients with chronic hepatitis B (CHB). J Hepatol 42 (2005) A36
22. Durantel S., Werle B., Durantel D., Pichoud C., Currie G., and Xiong S. Different profiles of response to adefovir dipivoxil and factors that may influence response in patients with chronic hepatitis B. Hepatology 40 (2004) A 1132
23. Lampertico P., Viganò M., Manetti E., Iavarone M., Lunghi G., and Colombo M. Adefovir rapidly suppresses hepatitis B in HBeAg-Negative patients developing genotypic resistance to lamivudine. Hepatology 42 (2005) 1414-1419
24. Villeneuve J.P., Durantel D., Durantel S., Westland C., Xiong S., and Brosgart C.L. Selection of a hepatitis B virus strain resistant to adefovir in a liver transplant patient. J Hepatol 39 (2003) 1085-1089
25. Brunelle M.N., Jaquard A.C., Pichoud C., Durantel D., Carrouee-Durantel S., Villeneuve J.P., et al. Susceptibility to antivirals of human HBV strain with mutations conferring resistance to both lamivudine and adefovir. Hepatology 41 (2005) 1391-1398
26. Moriconi F., Flichman D., Ciccorossi P., Coco B., Sacco R., Oliveri F., et al. HBV quasispecies selected during lamivudine treatment may contribute to adefovir dipivoxil resistance. J Hepatol 44 (2006) S188
27. Marcellin P., Chang T.T., lim S.G., Tong M.J., Sievert W., and Shiffman M.L. Adefovir dipivoxil for the treatment of hepatitis B e antigen positive chronic hepatitis B. N Engl J Med 348 (2003) 283-290
28. Tsiang M., Murray A., Rooney J., and Gibbs C.S. Effect of varying dose on the dynamics of HBV clearance from the serum of patients treated with adefovir dipivoxil. J Hepatol 30 (1999) GS2/12
29. Tsiang M., Rooney J.F., Toole J.J., and Gibbs C. Biphasic clearance of hBV from patients during adefovir dipivoxil. Hepatology 29 (1999) 1863c-1869c
30. Hézode C., Chevaliez S., Bouvier-Alias M., Roudot-Thoraval F., Brillet R., Zafrani E.-S., et al. Efficacy and safety of adefovir dipivoxil 20 mg daily in HBeAg-positive patients with lamivudine-resistant hepatitis B virus and a suboptimal virological response to adefovir dipivoxil 10 mg daily. J Hepatol 46 (2007) 791-796
31. Jedlitschky G., Burchell B., and Keppler D. The multidrug resistance protein 5 functions as an ATP-dependent export pump for cyclic nucleotides. J Biol Chem 275 (2000) 30069-30074
32. Lai Y., Tse C.M., and Unadkat J.D. Mitochondrial expression of the human equilibrative nucleoside transporter 1 (hENT1) results in enhanced mitochondrial toxicity of antiviral drugs. J Biol Chem 279 (2004) 4490-4497
33. Izzedine H., Launay-Vacher V., and Deray G. Antiviral drug-induced nephrotoxicity. Am J Kidney Dis 45 (2005) 804-817
34. Lee Y.S., Suh D.J., Lim Y.S., Jung S.W., Kim K.M., and Lee H.C. Increased risk of adefovir diivoxil resistance in patients with lamivudine resistant chronic hepatitis B after 48 weeks of adefovir monotherapy. Hepatology 43 (2006) 1385-1391
35. Colombatto P., Civitano L., Bizzarri R., Oliveri F., Choudhury S., Gieschke R., et al. Peginterferon Alfa-2a HBeAg-negative chronic hepatitis B study group. A multiphase model of the dynamics of HBV infection in HBeAg-negative patients during pegylated interferon-alpha2a, lamivudine and combination therapy. Antivir Ther 11 (2006) 197-212
36. Geretti A.M. Clinical implications of HIV drug resistance to nucleoside and nucleotide reverse transcriptase inhibitors. AIDS Rev 8 (2006) 210-220
37. Kantor R. Impact of HIV-1 pol diversity on drug resistance and its clinical implications. Curr Opin Infect Dis 19 (2006) 594-606